Treatment with anti-OX40L or anti-TSLP does not alter the frequency of T regulatory cells in allergic asthmatics

Allergy: European Journal of Allergy and Clinical Immunology

Volumn 70, Issue 11, 2015, Pages 1505-1508

  Baatjes, A J ^a   Smith, S G ^a   Dua, B ^a   Watson, R ^a   Gauvreau, G M ^a   O'Byrne, P M ^a  

^a MCMASTER UNIVERSITY   (Canada)

Author keywords

allergic asthma; flow cytometry; OX40L; T regulatory cell; thymic stromal lymphopoietin

Indexed keywords

ALLERGEN; ANTIASTHMATIC AGENT; MONOCLONAL ANTIBODY; OX40L ANTIBODY; THYMIC STROMAL LYMPHOPOIETIN ANTIBODY; UNCLASSIFIED DRUG; CYTOKINE; OX40 LIGAND; THYMIC STROMAL LYMPHOPOIETIN;

ADULT; ALLERGIC ASTHMA; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CD25+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; MALE; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; ANTAGONISTS AND INHIBITORS; ASTHMA; CD4 LYMPHOCYTE COUNT; FORCED EXPIRATORY VOLUME; IMMUNOLOGY; IMMUNOPHENOTYPING; METABOLISM; MIDDLE AGED; PATHOPHYSIOLOGY; TREATMENT OUTCOME; YOUNG ADULT;

ADULT; ANTIBODIES, MONOCLONAL; ASTHMA; CD4 LYMPHOCYTE COUNT; CYTOKINES; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; IMMUNOPHENOTYPING; MALE; MIDDLE AGED; OX40 LIGAND; T-LYMPHOCYTES, REGULATORY; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84945474163     PISSN: 01054538     EISSN: 13989995     Source Type: Journal    
DOI: 10.1111/all.12708     Document Type: Article

References (18)

1. Yu N, Li X, Song W, Li D, Yu D, Zeng X, et al., CD4(+)CD25 (+)CD127 (low/-) T cells: a more specific Treg population in human peripheral blood. Inflammation 2012; 35: 1773-1780.
2. Lloyd CM, Hawrylowicz CM,. Regulatory T cells in asthma. Immunity 2009; 18: 438-449.
3. Venuprasad K, Poojary KV, Kong Y-CM, Farrar MA,. Control of Th2-mediated inflammation by regulatory T cells. Am J Pathol 2010; 177: 525-531.
4. Ohkura N, Hamaguchi M, Sakaguchi S,. FOXP3+ regulatory T cells: control of FOXP3 expression by pharmacological agents. Trends Pharmacol Sci 2011; 32: 158-166.
5. De Serres SA, Yeung MY, Mfarrej BG, Najafian N,. Effect of biologic agents on regulatory T cells. Transplant Rev (Orlando) 2011; 25: 110-116.
6. Papierniak ES, Lowenthal DT, Harman E,. Novel therapies in asthma: leukotriene antagonists, biologic agents, and beyond. Am J Ther 2013; 20: 79-103.
7. Wang Y-H, Liu Y-J,. Thymic stromal lymphopoietin, OX40-ligand, and interleukin- 25 in allergic responses. Clin Exp Allergy 2009; 39: 798-806.
8. Watson B, Gauvreau GM,. Thymic stromal lymphopoietin: a central regulator of allergic asthma. Expert Opin Ther Targets 2014; 18: 771-785.
9. Liu Y-J,. Thymic stromal lymphopoietin and OX40 ligand pathway in the initiation of dendritic cell-mediated allergic inflammation. J Allergy Clin Immunol 2007; 120: 238-244.
10. Seshasayee D, Lee WP, Zhou M, Shu J, Suto E, Zhang J, et al., In vivo blockade of OX40 ligand inhibits thymic stromal lymphopoietin driven atopic inflammation. J Clin Invest 2007; 117: 3868-3878.
11. Voo KS, Bover L, Harline ML, Vien LT, Facchinetti V, Arima K, et al., Antibodies targeting human OX40 expand effector T cells and block inducible and natural regulatory T cell function. J Immunol 2013; 191: 3641-3650.
12. Lei L, Zhang Y, Yao W, Kaplan MH, Zhou B,. Thymic stromal lymphopoietin interferes with airway tolerance by suppressing the generation of antigen-specific regulatory T cells. J Immunol 2011; 186: 2254-2261.
13. Nguyen KD, Vanichsarn C, Nadeau KC,. TSLP directly impairs pulmonary Treg function: association with aberrant tolerogenic immunity in asthmatic airway. Allergy Asthma Clin Immunol 2010; 6: 4.
14. Gauvreau GM, Boulet L-P, Cockcroft DW, FitzGerald JM, Mayers I, Carlsten C, et al., OX40L blockade and allergen-induced airway responses in subjects with mild asthma. Clin Exp Allergy 2014; 44: 29-37.
15. Gauvreau GM, O'Byrne PM, Boulet L-P, Wang Y, Cockcroft D, Bigler J, et al., Effects of an anti-TSLP antibody on allergen-induced asthmatic responses. N Engl J Med 2014; 370: 2102-2110.
16. Kinoshita T, Baatjes A, Smith SG, Dua B, Watson R, Kawayama T, et al., Natural regulatory T cells in isolated early responders compared with dual responders with allergic asthma. J Allergy Clin Immunol 2014; 133: 696-703.
17. Xystrakis E, Urry Z, Hawrylowicz CM,. Regulatory T cell therapy as individualized medicine for asthma and allergy. Curr Opin Allergy Clin Immunol 2007; 7: 535-541.
18. Thorburn AN, Hansbro PM,. Harnessing regulatory T cells to suppress asthma: from potential to therapy. Am J Respir Cell Mol Biol 2010; 43: 511-519.